Laverock Therapeutics is changing course. The company has launched new in vivo CAR-T and genetic medicine programs. This move could shake up its pipeline and test the limits of current cell and gene therapy.
A 2026 independent review highlights that in vivo CAR-T therapies have already advanced into phase I clinical trials, with early data showing effective T-cell transduction and deep target cell depletion in non-human primate models.
In vivo CAR-T ambitions and solid tumor focus
Most in vivo CAR-T work so far has focused on blood cancers. Laverock wants to go after solid tumors. These make up about 90% of all cancer cases. The company says its gene control tech can help break through the barriers that have held back CAR-T in solid tumors. The goals are clear: better treatment, safer therapies, more patient access, and scalable manufacturing for CAR-T given directly in vivo. This is a big shift. Industry reviews point out that in vivo CAR-T has mostly targeted blood cancers. Solid tumors are a tougher problem. Delivery, safety, and the tumor microenvironment all make it harder.
A 2026 review notes that clinical development of in vivo CAR-T is accelerating, with ongoing studies such as NCT07413341 exploring the generation of CD19 CAR-T cells using lipid nanoparticles and circular RNA in patients with B-cell-mediated autoimmune diseases.
Genetic medicine and multiplex gene silencing
Laverock’s genetic medicine plan centers on in vivo gene silencing. The company is using direct delivery of gene editing tools to target diseases with high unmet need. The first targets are nervous system disorders and metabolic diseases. Existing gene editing and RNAi tools have struggled with precision and multiplexing in these areas. Laverock claims its tech can control several targets or pathways at once. This could help overcome those limits. But the company has not shared preclinical or clinical proof for these claims.
What makes Laverock’s approach different is the promise of multiplexed, programmable gene control in vivo. If it works, this could be a big step beyond current gene editing and RNAi. But as with many biotech platform expansions, the real test will be moving from concept to clinical results.
Laverock Therapeutics is betting on in vivo CAR-T and genetic medicine to solve some of the toughest problems in cell and gene therapy. The company’s claims are bold. But with no data or timelines released, the field is waiting for real progress. For now, Laverock’s move shows the race to go beyond ex vivo methods and reach the huge, underserved world of solid tumors and complex genetic diseases.
